Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06919081 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
A Phase 2 study of Persistent Corneal Epithelial Defect and Corneal Epithelial Disorders, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06919081: Recruiting Phase 2 study of Persistent Corneal Epithelial Defect and Corneal Epithelial Disorders, sponsored by University of Illinois at Chicago.
NCT06919081 is a Phase 2 study of Persistent Corneal Epithelial Defect and Corneal Epithelial Disorders that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06919081, a Phase 2 study of Persistent Corneal Epithelial Defect and Corneal Epithelial Disorders, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
Primary Outcome
Proportion of subjects with improved epithelial barrier and/or integrity from baseline to DAY 56 as determined by the investigator on slit lamp examination: · Improved epithelial barrier, defined as ³ 50 % improvement in corneal fluorescein staining score using NEI grading scale · Improved epithelial integrity, defined as complete closure of persistent epithelial defect, measured with ImageJ on slit lamp images
Conditions Studied
Interventions
- DRUG Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome
- OTHER Vehicle Control
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
What NCT06919081 shows while recruiting
NCT06919081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Persistent Corneal Epithelial Defect appearing as the primary indexed condition, and to 2 interventions - of which Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome is the first listed.
NCT06919081 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06919081 about?
NCT06919081 is a clinical study titled "Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease". In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for...
What is the current status of trial NCT06919081?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-08-01. Estimated completion is 2026-06-15.
What conditions does trial NCT06919081 study?
This clinical trial studies the following conditions: Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders.
What interventions are being tested in trial NCT06919081?
The interventions under investigation include: Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome (DRUG), Vehicle Control (OTHER).
Who is sponsoring clinical trial NCT06919081?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06919081 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Persistent Corneal Epithelial Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06919081's enrollment target sits among peer trials
24 1756th of 2000 higher than 218 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI